C6orf167 inhibitors pertain to a class of chemical compounds designed to interact with the protein encoded by the human gene C6orf167, also known as MICAL3 (molecule interacting with CasL protein 3). The name C6orf167 arises from its initial characterization as an open reading frame (ORF) on chromosome 6. The proteins in the MICAL family are known to be multi-domain flavoenzymes, which means they have the capacity to catalyze oxidation-reduction (redox) reactions using flavin adenine dinucleotide (FAD) as a cofactor. The precise biological function of C6orf167 is complex and multifaceted, involving the regulation of cytoskeletal dynamics. This includes its influence on actin filament disassembly and interactions with other proteins that are crucial for the maintenance of various cellular functions.
Inhibitors targeting C6orf167 are chemical agents that have been developed to specifically bind to this protein and modulate its activity. The design of such compounds typically stems from an understanding of the enzyme's structure and the key active sites that are essential for its enzymatic function. By binding to the MICAL3 protein, these inhibitors can affect the protein's ability to interact with its substrates or with other proteins within the cell. The development of inhibitors often involves the use of high-throughput screening techniques to identify potential molecules that demonstrate a high affinity for the target protein.
SEE ALSO...
Items 1 to 10 of 18 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea can inhibit DNA synthesis and might potentially disrupt processes where C6orf167 plays a role in DNA repair. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
By inhibiting the DNA enzyme topoisomerase I, camptothecin may impact DNA dynamics and indirectly affect C6orf167 functionality. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide targets topoisomerase II. Altered DNA topology might interfere with the roles C6orf167 plays in DNA repair. | ||||||
1-β-D-Arabinofuranosylcytosine | 147-94-4 | sc-201628 sc-201628A sc-201628B sc-201628C sc-201628D | 1 g 5 g 25 g 100 g 250 g | $147.00 $258.00 $508.00 $717.00 $1432.00 | 1 | |
1-β-D-Arabinofuranosylcytosine disrupts DNA synthesis. This disruption could indirectly influence processes where C6orf167 functions. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Olaparib is a PARP inhibitor. While not directly targeting MMS22L, PARP inhibition can modulate DNA repair pathways in which C6orf167 might be involved. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $279.00 | 8 | |
Mitoxantrone intercalates into DNA. This intercalation might indirectly alter processes where C6orf167 plays a role. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
By intercalating DNA and affecting topoisomerase II, doxorubicin could potentially influence C6orf167 functionality. | ||||||
2′-Deoxy-2′,2′-difluorocytidine | 95058-81-4 | sc-275523 sc-275523A | 1 g 5 g | $56.00 $128.00 | ||
As a nucleoside analog, gemcitabine may interfere with DNA replication processes, potentially impacting C6orf167's roles. | ||||||
Bleomycin Sulfate | 9041-93-4 | sc-200134 sc-200134A sc-200134B sc-200134C | 10 mg 50 mg 100 mg 500 mg | $206.00 $612.00 $1020.00 $2856.00 | 38 | |
Bleomycin causes DNA breaks. Inducing such damage might overload or compete with the pathways C6orf167 is involved in. | ||||||
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
Aphidicolin is a DNA polymerase inhibitor. It might indirectly impact C6orf167 functionality by stalling replication. |